Insmed Discontinues Brensocatib Development In Hidradenitis Suppurativa After Phase 2b Results

Phase 2b CEDAR study of brensocatib in adults with moderate-to-severe hidradenitis suppurativa failed to meet its primary and secondary efficacy endpoints in both the 10 mg and 40 mg arms. This clinical failure materially weakens the drug's near-term commercial potential and is likely negative for Insmed's valuation and near-term share performance; reassess pipeline exposure and any dependent revenue assumptions.

Analysis

Phase 2b CEDAR study of brensocatib in adults with moderate-to-severe hidradenitis suppurativa failed to meet its primary and secondary efficacy endpoints in both the 10 mg and 40 mg arms. This clinical failure materially weakens the drug's near-term commercial potential and is likely negative for Insmed's valuation and near-term share performance; reassess pipeline exposure and any dependent revenue assumptions.